1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
-
Mark
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
(
- Contribution to journal › Article
- 2014
-
Mark
Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib
(
- Contribution to journal › Article
-
Mark
Comparison of MRD monitoring by IG/TR rearrangement and BCR/ABL1 transcript in PH+ pediatric acute lymphoblastic leukemia patients treated with imatinib in the EsPhALL study
(
- Contribution to journal › Published meeting abstract
- 2012
-
Mark
Adjuvant therapy in primary GIST: state-of-the-art
(
- Contribution to journal › Scientific review
- 2011
-
Mark
Efficacy and safety of imatinib on top of BFM-like chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL). the EsPhALL study
(
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation
(
- Contribution to journal › Article